Trusted results

Trusted results

Trained with 1M+ cell annotations by 150+ pathologists worldwide to generate validated, reliable results.
Reduced discrepancy

Reduced discrepancy

Reduce interpretation discrepancies between readers with objective results.
Seamless interoperability

Seamless interoperability

Offers seamless interoperability with integration into platforms including Leica Biosystems' Aperio AI Store, Indica Labs' HALO AP®, and Roche navify®.

AI-Powered Detection and Classification of PD-L1 Expression

Lunit SCOPE PD-L1 assists in detecting and classifying PD-L1 biomarker expression by analyzing digitized IHC whole slide images from formalin-fixed paraffin embedded (FFPE) tissue.

It supports consistent, quantitative assessment of PD-L1 status and is designed to enhance productivity.

Click to See the Publication
AI-Powered Detection and Classification of PD-L1 Expression

Proven AI-Powered Speed and Accuracy

Bar charts showing that AI-assisted PD-L1 analysis improved objective response rate from 2.3% to 15% and progression-free survival from 1.8 to 2.7 months in edge cases initially scored as negative.

Improves accuracy

Lunit SCOPE PD-L1 enhances scoring accuracy for complex images, including edge or ambiguous samples1.

¹Kim H. et al. 2024. Clinical Validation of Artificial Intelligence–Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non–Small Cell Lung Cancer, JCO Precis Oncol, 2024;8: e2300556

View Clinical Evidence
Line chart showing PD-L1 scoring discrepancies among pathologists reduced from 32.1% to 10.3% with AI assistance, improving scoring agreement for tumor proportion scores below 1%.

Enhances scoring agreement

Lunit SCOPE PD-L1 delivers objective, reliable analysis results with proven support for reading consistency and improved scoring agreement.²

²Choi S. et al. 2022. AI–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction

View Clinical Evidence

Shortens reading time

Lunit SCOPE PD-L1 can improve efficiency by reducing reading time by 32%.³

³Kim S. et al. 2022. Observer performance study to examine the feasibility of the AI-powered PD-L1 analyzer to assist pathologists’ assessment of PD-L1 expression using tumor proportion score in non–small cell lung cancer, JCO, 2022;40(16)

View Clinical Evidence
Infographic showing average PD-L1 reading time reduced by 32%, from 285 seconds without AI to 195 seconds with AI support.

AI Pathology Software Built to Support Accuracy and Productivity

Lunit SCOPE PD-L1 is integrated into digital pathology platforms, including Leica Biosystems' Aperio AI Store, Indica Labs' HALO AP®, and Roche navify®. It empowers research and pharma worldwide with ease of use, seamless operability, powerful analytics, and unmatched processing speeds in digital pathology—enabling quantitative tissue analysis with precision and efficiency.
Experience Lunit SCOPE PD-L1 Now

Featured News & Publications

Stay informed with the latest research, product updates, and global partnerships driving innovation in AI-powered precision oncology.

See All News & Publications
Media Hub

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

Media Hub

Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials

Publication

Leveraging artificial intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: Translational analyses of AtezoTRIBE and AVETRIC trials

Featured Resources

Explore white papers, product guides, and educational tools designed to help you get the most from Lunit’s AI-powered oncology solutions.

See All Resources
One Pager

Lunit SCOPE PD-L1 on Roche Navify

Video

Lunit SCOPE PD-L1 on Roche Navify video

Related Solutions

Lunit SCOPE HER2

Improve accuracy with AI-assisted ultralow expression analysis.

Explore Lunit SCOPE HER2

For Research Use Only. Not for use in diagnostic procedures or decisions

Lunit SCOPE uIHC

Accelerate IHC-based biomarker development and enrich clinical trials.

See Lunit SCOPE uIHC

For Research Use Only. Not for use in diagnostic procedures or decisions

Lunit SCOPE GP

Extract AI-powered genotype prediction for screening and discovery.

View Lunit SCOPE GP

For Research Use Only. Not for use in diagnostic procedures or decisions

Lunit SCOPE IO

Unlock TME insights with AI-powered immune phenotyping.

View Lunit SCOPE IO

For Research Use Only. Not for use in diagnostic procedures or decisions.
Boost Your Efficiency with Fast, Accurate Insights

Boost Your Efficiency with Fast, Accurate Insights

Equip your team with PD-L1 quantification software that improves accuracy, reduces inter-observer variability, and improves workflow efficiency.
Contact Us

Frequently Asked Questions

What differentiates you as a partner in AI-powered image analysis?

Our deep expertise, robust clinical evidence, and partnerships with many CROs and digital pathology platform providers set us apart. We prioritize collaboration and offer versatile solutions that are compatible with a wide range of scanners and IMS.